Brief: Zealand Pharma Enters Into $100 Mln Royalty Purchase, Sale Agreement With Royalty Pharma
13/08/2026 06:25
BRIEF-Zealand Pharma Enters Into $100 Mln Royalty Purchase, Sale Agreement With Royalty Pharma Aug 13 (Reuters) - Zealand Pharma A/S ZELA.CO:
SAID ON WEDNESDAY ENTERED INTO A USD 100 MILLION ROYALTY PURCHASE AND SALE AGREEMENT WITH ROYALTY PHARMA FOR THE ECONOMICS RELATED TO RUSFERTIDE
Source text: ID:nGNE2dKrYf
Further company coverage: ZELA.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)